Contraindications & Patient Selection

Evidence-based screening criteria for safe medicinal leech therapy

Last Updated: March 18, 2026Reviewed by: Andrei Dokukin, MDRegulatory Status: Clinical Evidence (Tier 2)

Clinical Evidence — Not FDA-Evaluated

This page consolidates patient selection criteria and contraindication data from published clinical guidelines, systematic reviews, and institutional protocols. Practitioners must adapt screening to their specific clinical setting and comply with applicable scope-of-practice laws.

Absolute Contraindications

Absolute contraindications represent conditions where medicinal leech therapy must not be performed under any circumstances. The presence of any absolute contraindication requires immediate discontinuation of treatment planning.

Hemophilia & Hemorrhagic Diathesis

Patients with hemophilia A/B, von Willebrand disease, or other inherited bleeding disorders. Leech-induced bleeding cannot be controlled with standard hemostatic measures due to the presence of hirudin (direct thrombin inhibitor), calin (platelet aggregation inhibitor), and factor Xa inhibitors in salivary gland secretion.

Active Anticoagulation Therapy

Current use of warfarin (INR >1.5), heparin, or direct oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban). Anticoagulants must be discontinued and coagulation parameters normalized before treatment. Exception: post-thrombotic syndrome protocols under vascular medicine supervision with standardized bleeding assessment.

Active Septicemia

Systemic infection with bacteremia. Leech application introduces Aeromonas spp. (obligate gut symbiont) into the wound, creating dual infection risk. Treatment must be deferred until systemic infection is fully resolved.

Severe Anemia

Hemoglobin <8 g/dL without active transfusion support. Each leech removes 5–15 mL during feeding plus 50–150 mL post-detachment oozing (4–24 hours). Multiple leeches can produce clinically significant blood loss. ~50% of microsurgical leech therapy patients require transfusion (Whitaker 2012).

Prior Anaphylaxis to Leech SGS

Documented IgE-mediated anaphylactic reaction to leech salivary gland secretion. Note: mild histamine-mediated local reactions (itching, erythema) occur in 37–75% of patients and are NOT a contraindication. Only confirmed systemic anaphylaxis (urticaria, angioedema, bronchospasm, hypotension) constitutes an absolute contraindication.

Hematological Malignancies

Active leukemia, lymphoma, or myeloproliferative disorders. These conditions cause qualitative and quantitative platelet dysfunction, impaired coagulation factor synthesis, and immunocompromise — compounding both bleeding and infection risk.

Decompensated Hepatobiliary Disease

Severe liver disease with coagulopathy (INR >1.5, platelet count <50,000/μL). Impaired synthesis of coagulation factors and thrombocytopenia from portal hypertension create unacceptable bleeding risk.

Arterial Insufficiency at Application Site

Severe peripheral arterial disease (ABI <0.5) at the intended treatment site. Leech therapy produces local venous decompression — in the setting of arterial insufficiency, this may worsen tissue ischemia by reducing already-compromised perfusion pressure.

Relative Contraindications

Relative contraindications require individualized risk-benefit analysis. Treatment may proceed with appropriate precautions, modified protocols, or specialist consultation.

Aspirin & NSAID Use

Moderate

Increased bleeding duration due to platelet inhibition. Consider withholding aspirin 7–10 days and NSAIDs 3–5 days before elective treatment. In emergency microsurgical salvage, proceed with enhanced monitoring.

Mitigation: Withhold if elective; serial hematocrit monitoring q4-8h; maintain cross-matched blood availability

Diabetes Mellitus

Moderate

Increased infection risk due to impaired neutrophil function, peripheral neuropathy (inability to detect bite-site pain), and peripheral arterial disease (impaired bite wound healing).

Mitigation: Mandatory antibiotic prophylaxis; HbA1c <10% and ABI ≥0.7 for diabetic foot applications; enhanced wound monitoring

Immunosuppressive Therapy

Moderate–High

Transplant recipients, autoimmune disease patients on biologics, or corticosteroid therapy. Increased Aeromonas infection risk and impaired wound healing.

Mitigation: Extended antibiotic prophylaxis (7–14 days); infectious disease consultation; enhanced wound surveillance

Pregnancy

High (insufficient data)

No controlled studies in pregnant women. Theoretical concerns: hirudin crosses placental barrier (molecular weight 7 kDa); post-detachment bleeding may cause maternal anemia; Aeromonas infection risk to fetus unknown.

Mitigation: Avoid unless no alternatives exist and maternal benefit clearly outweighs potential fetal risk. Requires OB/GYN consultation.

Keloid Tendency

Low–Moderate

Leech bites leave permanent triradiate scars (2–5 mm). Patients with known keloid formation may develop hypertrophic scarring at bite sites.

Mitigation: Informed consent with explicit scar disclosure; consider silicone sheeting post-healing; avoid cosmetically sensitive areas

Antiplatelet Therapy (Clopidogrel, Ticagrelor)

Moderate–High

Dual antiplatelet therapy (DAPT) creates compounded bleeding risk. Discontinuation may not be safe in patients with recent coronary stent placement.

Mitigation: Cardiology consultation required; risk-benefit analysis for each case; enhanced hematologic monitoring

Drug Interactions

Medicinal leech salivary gland secretion contains multiple pharmacologically active compounds that interact with anticoagulant, antiplatelet, and anti-inflammatory medications. The table below summarizes clinically significant interactions.

Medication Class	Severity	Mechanism	Management
Warfarin	High	Additive anticoagulation: warfarin (vitamin K antagonist) + hirudin (direct thrombin inhibitor) + factor Xa inhibitors in SGS	Discontinue and normalize INR (<1.5) before treatment. Bridge with LMWH if clinically indicated.
Direct Oral Anticoagulants (DOACs)	Moderate–High	Dabigatran: direct thrombin inhibitor (same target as hirudin — competitive). Rivaroxaban/apixaban: factor Xa inhibitors (same target as SGS antistasin).	Discontinue ≥48 hours before elective treatment (≥72h if CrCl <50 mL/min). Idarucizumab available for dabigatran reversal in emergencies.
Heparin (UFH/LMWH)	High	Antithrombin III potentiation (heparin) + direct thrombin inhibition (hirudin) = profound anticoagulation	Discontinue and confirm normalized aPTT/anti-Xa levels before treatment.
Aspirin	Moderate	Irreversible COX-1 inhibition (aspirin) + calin/saratin-mediated platelet inhibition (SGS) = compounded antiplatelet effect	Withhold 7–10 days for elective cases. In emergency microsurgical salvage, proceed with enhanced monitoring.
NSAIDs (Ibuprofen, Naproxen, etc.)	Moderate	Reversible COX inhibition + SGS antiplatelet compounds = extended bleeding	Withhold 3–5 days before elective treatment. Monitor for prolonged post-detachment bleeding.
Thrombolytics (tPA, Streptokinase)	Very High	Systemic fibrinolysis + local anticoagulation from SGS = uncontrollable hemorrhage risk	Absolute contraindication during active thrombolytic therapy. Wait ≥24 hours after tPA completion.

Special Populations

Pediatric Patients (<18 years)

•Limited clinical evidence in children; most data from microsurgical case reports
•Relative contraindication in children under 6 years (low blood volume, cooperation concerns)
•Fluoroquinolones contraindicated under age 18 — use TMP-SMX + 3rd-generation cephalosporin for prophylaxis
•Blood volume calculation required: neonates ~80 mL/kg, children ~70 mL/kg — even single-leech blood loss may be hemodynamically significant
•Enhanced parental informed consent and continuous monitoring required

Elderly Patients (>65 years)

•Comprehensive polypharmacy review required (anticoagulants, antiplatelets, NSAIDs, SSRIs)
•Reduced blood volume tolerance — lower transfusion threshold (Hgb <8 g/dL with cardiovascular disease)
•Renal dose adjustment for fluoroquinolone prophylaxis (CrCl-based dosing)
•Increased skin fragility — consider reduced leech application duration
•Extended post-procedure observation (minimum 6 hours)

Immunocompromised Patients

•HIV/AIDS, active chemotherapy, transplant recipients, biologics therapy
•Extended antibiotic prophylaxis course (7–14 days) with broader spectrum coverage
•Infectious disease consultation recommended before initiating therapy
•Enhanced wound surveillance with culture at first sign of infection
•Consider alternative therapies (chemical leeching, heparin pledgets) if infection risk exceeds benefit

Pregnancy & Lactation

•No controlled studies in pregnant or lactating women
•Hirudin (molecular weight ~7 kDa) may cross the placental barrier — unknown fetal effects
•Post-detachment bleeding may cause maternal anemia, potentially compromising fetal oxygenation
•Aeromonas infection risk to fetus: unknown, but Aeromonas bacteremia carries significant mortality
•Recommendation: avoid unless maternal benefit clearly outweighs potential fetal risk; OB/GYN consultation mandatory

Emergency Preparedness

All facilities performing leech therapy must have protocols for managing the following complications:

Hemorrhage

Apply direct pressure with hemostatic gauze. If bleeding persists >30 minutes: silver nitrate cautery to bite site. If hemodynamically significant: activate massive transfusion protocol. Monitor: serial Hgb/Hct q4h during active treatment.

Anaphylaxis

Standard anaphylaxis protocol: epinephrine 0.3–0.5 mg IM (1:1000), IV access, fluid resuscitation, airway management. Document SGS allergy prominently in medical record. Contraindicate future leech therapy.

Aeromonas Infection

Early signs: erythema, warmth, purulent drainage at bite site within 24–72 hours. First-line: ciprofloxacin 500 mg PO BID + TMP-SMX DS PO BID. Obtain wound culture before antibiotics if feasible. If systemic: blood cultures, IV antibiotics (ciprofloxacin + aminoglycoside), surgical consultation.

Leech Migration

Prevent: apply leeches within a barrier (e.g., gauze dam). If leech migrates to body cavity: do NOT pull — apply salt or vinegar to induce detachment. ENT/surgical consultation for aerodigestive tract migration. Document and report as adverse event.

Critical Reminder

Antibiotic prophylaxis is mandatory for all leech therapy applications. Aeromonas infection reduces microsurgical salvage rates from 88.3% to 37.4% — a 51-percentage-point decline. Ciprofloxacin monotherapy is increasingly unreliable (43% environmental resistance); combination therapy with TMP-SMX is recommended.

Informed Consent Requirements

Practitioners must obtain documented informed consent that specifically discloses: (1) bleeding risk (4–24 hours post-detachment, ~50% transfusion rate in microsurgery), (2) infection risk (Aeromonas, 2–5% with prophylaxis, 7–20% without), (3) permanent scarring (triradiate marks, 2–5 mm), (4) off-label status if applicable.